This ‘regain-of-function’ improves the clearance of cancer cells but also leads to unwanted removal of the anti-CD47-sensitive normal cells such as erythrocytes or platelets, causing transient anemia or thrombocytopenia in treated patients (20, 26). Here, CD47 is linked to cancer.